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KRAS is the most frequently mutated oncogene in human tumors, and its activating mutations represent important thera-
peutic targets. The combination of Cas9 and guide RNA from the CRISPR-Cas system recognizes a specific DNA sequence
and makes a double-strand break, which enables editing of the relevant genes. Here, we harnessed CRISPR to specifically
target mutant KRAS alleles in cancer cells. We screened guide RNAs using a reporter system and validated them in cancer
cells after lentiviral delivery of Cas9 and guide RNA. The survival, proliferation, and tumorigenicity of cancer cells in vitro
and the growth of tumors in vivo were determined after delivery of Cas9 and guide RNA. We identified guide RNAs that
efficiently target mutant KRASwithout significant alterations of the wild-type allele. Doxycycline-inducible expression of this
guide RNA in KRAS-mutant cancer cells transduced with a lentiviral vector encoding Cas9 disrupted the mutant KRAS gene,
leading to inhibition of cancer cell proliferation both in vitro and in vivo. Intra-tumoral injection of lentivirus and adeno-
associated virus expressing Cas9 and sgRNA suppressed tumor growth in vivo, albeit incompletely, in immunodeficient
mice. Expression of Cas9 and the guide RNA in cells containing wild-type KRAS did not alter cell survival or proliferation
either in vitro and in vivo. Our study provides a proof-of-concept that CRISPR can be utilized to target driver mutations of
cancers in vitro and in vivo.
[Supplemental material is available for this article.]
The RAS subfamily member KRAS is the most frequently mutated
oncogene in cancers, including highly lethal lung, colon, and pan-
creatic cancers (Cox et al. 2014). Activating mutations in KRAS
play potent roles in cancer initiation, propagation, and mainte-
nance, representing important therapeutic targets (Cox et al.
2014). However, despite more than three decades of substantial ef-
fort by academia and industry, activating KRASmutations remain
a critical challenge because few effective and specific inhibitors for
these mutations are available, necessitating other approaches to
target KRASmutations. Although the obstacle of targeting mutant
KRAS could be partly overcome with the recent development of
KRASG12C-specific inhibitors (Ostrem et al. 2013; Patricelli et al.
2016) and a RAS-binding domain inhibitor that is not selective
for mutant RAS (Athuluri-Divakar et al. 2016), mutation-specific
inhibition was not achieved using small molecules for KRASG12D
or KRASG12V, which occur more frequently than KRASG12C. Small
interfering RNAs (siRNAs) that selectively inhibit mutant KRAS
mRNAs (Brummelkamp et al. 2002), but not their origin DNA,
lead to knockdown, rather than complete knockout, of themutant
mRNA, and their continuous expression or delivery is required for
target RNA suppression (Zorde Khvalevsky et al. 2013). Methods
for targeting the oncogenic KRASmutations themselves in cancer
cells in vivo have yet to be reported.
Programmable nucleases, which include zinc finger nucleas-
es, transcriptional activator-like effector nucleases, and CRISPR-
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Cas (clustered regularly interspaced short palindromic repeats and
CRISPR-associated proteins), recognize specific DNA sequences
and make double-strand breaks, the repair of which can lead to
indel formation at the target sites by error-prone nonhomologous
end joining (NHEJ) (Jinek et al. 2012; Cong et al. 2013; Mali et al.
2013; Kim and Kim 2014). This indel formation can lead to disrup-
tion of the corresponding gene (Jinek et al. 2012; Cong et al. 2013;
Mali et al. 2013; Kim and Kim 2014; Kim et al. 2015). Thus, we
expected that we could disrupt mutant KRAS alleles, but not
wild-typeKRAS, usingCas9 and guide RNAs that specifically recog-
nize the mutant sequences.
Here,we attempted to identify guide
RNAs that specifically target mutant, but
not wild-type, KRAS. We also evaluated
whether the delivery of Cas9 and a guide
RNA targeting mutant KRAS into cancer
cells would affect the survival, prolifera-
tion, and tumorigenicity of the cultured
cancer cells in vitro and the tumor
growth in vivo.
Results
Selection of guide RNAs that target
mutant KRAS
To target mutant KRAS alleles in cancer
cells with the CRISPR-Cas9 system, we
first screened for guide RNAs that specif-
ically target KRAS mutations, including
c.35G>T (p.G12V), c.35G>A (p.G12D),
and c.38G>A (p.G13D) (Supplemental
Fig. S1), but not wild-type KRAS. Most
cancer cell lines containing KRAS muta-
tions also have a wild-type KRAS allele
in their genome; indels generated at the
mutant allele are hard to distinguish
from indels at the wild-type allele, mak-
ing it difficult to find mutant-specific
guide RNAs using these cell lines. Thus,
we adopted our surrogate NHEJ reporter
system that enables the evaluation of
guide RNA activity (Kim et al. 2011;
Ramakrishna et al. 2014). These reporters
contain a monomeric red fluorescent
protein (mRFP) gene, CRISPR-Cas9 target
sequences, and two enhanced green fluo-
rescent protein (eGFP) genes (Supple-
mental Fig. S2). The reporters express
eGFP only when frame-shifting indels
such as (3n + 1) or (3n + 2) nucleotide in-
sertions or deletions are generated at the
target sequences in the reporter plasmid.
To identify guide RNAs that specifically
and efficiently target mutant, but not
wild-type, KRAS, we cotransfected a re-
porter plasmid containing the mutant
or wild-type KRAS sequence as the target,
a plasmid encoding Cas9, and a plasmid
encoding a single guide RNA (sgRNA)
into HEK293T cells. We then subjected
the transfected cells to flow cytometry
to determine the percentage of cells expressing both mRFP and
eGFP normalized to that of cells only expressingmRFP, which rep-
resents the activity of the guide RNA on the target sequence. Some
guide RNAs resulted in highGFP expressionwith themutant target
sequence and low expression with the wild-type sequence (Fig. 1;
Supplemental Fig. S3), suggesting that they were selectively and ef-
ficiently targeting the mutant KRAS sequences. For subsequent
studies, we selected three guide RNAs: two with high targeting
selectivity (35T9P17 and 38A6P17) and one with low targeting
selectivity (35A9P17) for mutant KRAS.
Figure 1. Reporter-based selection of sgRNAs that target mutant KRAS. The ratios of eGFP+mRFP
+/eGFP+ cells after transfection of reporters with mutant (c.35G>T [A], c.35G>A [B], or c.38G>A
[C ]) or wild-type target sequences, which reflect guide RNA activities at the target sequences, are
shown on the left in the two-dimensional graphs. Black and red lines in the graphs represent ratios
of eGFP+mRFP+/mRFP+ cells for mutant vs. wild-type KRAS target sequences with values of 1 and 3,
respectively. The target sequence of each sgRNA is shown on the right side; the KRAS point mutation
site is shown in red and the protospacer adjacent motif sequence is in blue. sgRNAs selected for sub-
sequent studies are indicated with black arrows in the two-dimensional graphs and their names are
shown in bold.
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Cas9 and sgRNA-directed selective and efficient disruption
of mutant KRAS in cancer cells
To validate the function of these selected guide RNAs at the
endogenous targets, we next transduced cancer cells containing
these mutations with lentiviral vectors encoding Cas9 and the
corresponding guide RNAs (Supplemental Fig. S4). Deep sequenc-
ing showed that delivery of Cas9 and the 35T9P17 sgRNA resulted
in indel frequencies of 50% in SW403 cells, which are heterozy-
gous for the c.35G>T mutation, and 81% and 80% in SW480
and SW620 cells, respectively, which are homozygous for the
c.35G>T mutation, leading to a drastic reduction of mutant
KRAS: from 70%, 100%, 100% to 12%, 19%, 20%, respectively
(Fig. 2A–C,G; Supplemental Figs. S5A–C, S6A). Similarly, lentiviral
delivery of Cas9 and 35A9P17 or 38A6P17 into LS513 cells, which
are heterozygous for the c.35G>A mutation, or LoVo cells, which
are heterozygous for the c.38G>Amutation, leads to indel frequen-
cies of 36% or 28%, respectively (Fig. 2D,E; Supplemental Fig.
S5D,E). As a result, mutant KRAS was reduced from 53% or 67%
to 20% or 22% (Fig. 2G; Supplemental Fig. S6B,C). When these
guide RNAs were lentivirally delivered into HT29 cells, which
contain wild-type KRAS, the indel frequencies were 0.2% for
35T9P17, 77% for 35A9P17, and 0.3% for 38A6P17 (Fig. 2F;
Supplemental Fig. S5F), indicating that 35T9P17 and 38A6P17,
but not 35A9P17, are highly selective for mutant, but not wild-
type, KRAS. These indel frequencies at the endogenous sites are
basically compatible with the reporter assay results described
above.Whenwe conducted a similar test using a lentivirus that ex-
presses 35T9P17 in a doxycycline-inducible manner, we observed
similar results (Supplemental Fig. S7), corroborating that 35T9P17
is a highly selective and efficient guide RNA targeting c.35G>T
KRAS (p.G12V).
When we analyzed the indel sequences, we identified a
diverse set of sequences and observed that roughly one third of
them were in-frame (Supplemental Fig. S8). Given that the se-
quences near the cleavage site encode an important functional
domain of KRAS (Ostrem et al. 2013; Hunter et al. 2015) and
that targeting functional domains can lead to loss-of-function
even when in-frame variants are generated (Shi et al. 2015), these
in-frame indels may lead to loss-of-function of mutant KRAS.
Targeting mutant KRAS with CRISPR-Cas9 inhibits cancer
cell survival, proliferation, and tumorigenicity in vitro
We next determined whether such disruption of mutant KRAS
could affect cancer cell survival, proliferation, and tumorigenicity
in vitro. Cancer cells were first transducedwithCas9-encoding len-
tiviral vectors and then transduced with guide RNA-encoding vec-
tors. These transduced cells were subjected to colony forming and
soft agar assays. Expression of Cas9 and the 35T9P17 sgRNA in
SW403 cells, which are heterozygous for c.35G>T, led to 94%
and 70% reductions in the number of colonies in colony forming
and soft agar assays, respectively, suggesting that disruptionofmu-
tant KRAS using Cas9 and sgRNA inhibits the survival and tumor-
igenicity of the KRASmutant cancer cells (Fig. 3A,E). A similar Cas9
and 35T9P17 sgRNA-induced reduction in the number of colonies
in both assays was also observed in SW480 and SW620 cells, which
are homozygous for the c.35G>T KRAS mutation (Supplemental
Fig. S9A–D). Furthermore, expression of Cas9 and the 35A9P17
sgRNA in LS513 cells, which are heterozygous for c.35G>A,
resulted in 91% and 96% reductions in the number of colonies
in colony forming and soft agar assays, respectively, indicating in-
hibition of survival and tumorigenicity (Fig. 3B,F). The expression
of Cas9 and the 38A6P17 sgRNA also reduced the number of colo-
nies in both assays, but the reduction
was, albeit significant, only 25% and
61%, respectively (Fig. 3C,G), suggesting
that a sgRNA with low activity only par-
tially inhibits the survival and tumorige-
nicity of KRAS mutant cancer cells. The
expression of Cas9 and these sgRNAs in
HT29 cells did not change the number
of colonies in either assay (Fig. 3D,H),
suggesting that reduction of survival
and tumorigenicity by Cas9 and these
sgRNA is restricted to KRASmutant cells.
In addition, we expressed guide RNA in a
doxycycline-inducible manner in cells
transduced with a lentiviral vector that
constitutively expresses Cas9. This doxy-
cycline-inducible guide RNA expression
selectively inhibited colony formation
in SW403, SW480, and SW620 cells,
which contain c.35G>T KRAS, but not
in HT29 cells, which contain wild-type
KRAS (Supplemental Fig. S10), corrobo-
rating that Cas9 and the 35T9P17
sgRNA selectively suppress survival and
tumorigenicity of KRAS c.35G>T mutant
cells, but not cells containing wild-type
KRAS, in vitro.
We also evaluated the effect of Cas9
and guide RNAon cell proliferationusing
MTS and xCELLigence cell proliferation
Figure 2. Cas9 and sgRNA-directed selective and efficient disruption of mutant KRAS in cancer cells.
Cas9 and sgRNAs were delivered into cancer cells and the indel frequencies at the endogenous target
sequences were evaluated by deep sequencing. Untreated cells were used as the control. The names
of the cancer cell lines and their related mutations are shown at the top of each graph. (Hetero.)
Heterozygous, (Homo.) homozygous. (A–F) Indel frequencies in cancer cells after delivery of Cas9 and
sgRNA. Error bars represent SEM. (G) Average sequence frequencies. The values from each experiment
are shown in Supplemental Figure S6. Red = Indels, green = wild-type KRAS (unedited), purple =mutant
KRAS (unedited).
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assays. After lentiviral delivery of Cas9 and guide RNA, live cells
were counted and 5000 cells were plated into 96-well (for the
MTS assay) or 16-well plates (for the xCELLigence assay).
Performance of the MTS assay at 48 h after plating showed that
the relative viable cell number in the population expressing Cas9
and the 35T9P17 RNA were, on average, 0.34, 0.46, and 0.71 in
SW403, SW480, and SW620 cells, respectively (Fig. 3I; Supplemen-
tal Fig. S9E,F), suggesting that mutant KRAS disruption using Cas9
and sgNA inhibits cell proliferation or survival. Similarly, lentiviral
delivery of Cas9 and 35A9P17 sgRNA into LS513 cells and that of
Cas9 and 38A6P17 sgRNA into LoVo cells resulted in a significant
reduction of the relative viable cell number to 0.18 and 0.69, re-
spectively (Fig. 3J,K). A real-time cell proliferation assay using
xCELLigence showed that the cell index started to decrease about
Figure 3. Targeting mutant KRAS with CRISPR-Cas9 inhibits cancer cell survival, proliferation, and tumorigenicity in vitro. Cancer cells containing KRAS
mutations were subjected to colony forming (A–D), soft agar (E–H), andMTS (I–L) assays after lentiviral delivery of Cas9 and sgRNAs targetingmutant KRAS.
A completely different sequence-targeting guide RNAwithout activity was used as the control (negative control). (Hetero.) Heterozygous, (Homo.) homo-
zygous. Error bars represent SEM. (∗) P < 0.05, (∗∗) P < 0.01, (∗∗∗) P < 0.001. (A–D) Colony forming assay. Representative images of wells after 2% crystal
violet staining are shown at the top of each graph. (E–H) Soft agar assay. Representative images of formed colonies are shown at the top of each graph. Scale
bar = 100 µm. (I–L) MTS assay. One day after the final transduction, untransduced cells were removed using puromycin selection for 24 h, after which 5000
cells per sample were plated onto 96-well plates. Cell proliferation was determined by use of MTS reagents 48 h after plating. The relative number of cells in
cultures transduced with active versus negative control sgRNAs was determined by normalizing the optical density at 490 nm of each MTS reaction to the
average optical density of the negative control reactions.
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24 h after plating (72 h after lentiviral
delivery of Cas9 and guide RNA)
(Supplemental Fig. S11A–C), suggesting
that mutant KRAS disruption causes
KRASmutant cells to die. The expression
of Cas9 and sgRNAs in HT29 cells did not
alter the number of colonies formed on
culture dishes or in soft agar (Fig. 3D,
H), the number of cells measured by
MTS reagents (Fig. 3L), or cell index
(Supplemental Fig. S11D), suggesting
that targeting mutant KRAS with Cas9
and sgRNA does not affect proliferation
or survival of this wild-type KRAS-con-
taining cell line. Furthermore, the find-
ing that 35A9P17 results in indel
generation at significantly high frequen-
cy at wild-type KRAS in HT29 cells (Fig.
2F) indicates that these cells are not de-
pendent on KRAS, which is in line with
a previous report (Baumer et al. 2015).
Targeting mutant KRAS with CRISPR-
Cas9 blocks tumor growth in vivo
Wenext evaluatedwhether targetingmu-
tant KRAS can suppress tumor growth in
vivo. To express the 35T9P17 sgRNA in
vivo after tumor formation, Cas9-ex-
pressing SW403 cells were first generated
using lentiviral vector transduction. The
cells were subsequently transduced with
another lentiviral vector that expresses
the 35T9P17 sgRNA in a doxycycline-in-
ducible manner (Supplemental Fig. S4B;
Aubrey et al. 2015). Subcutaneous trans-
plantation of these double-transduced
cancer cells into athymic nude mice led
to tumor formation over 14 d. Then, dox-
ycycline was administered to the mice to
induce 35T9P17 sgRNA expression in the
tumor cells. This guide RNA expression
dramatically inhibited tumor growth
(Fig. 4A,B); tumor weights measured at
day 26 (12 d after the start of doxycycline
treatment) in the doxycycline group
were 7.2-fold lower than those in the con-
trol group (Fig. 4E,G). Similarly, tumor
weights were 10-fold reduced by doxycy-
cline-induced expression of sgRNA in a
different cancer cell line, SW480, which
is homozygous for c.35G>T (Supplemen-
tal Fig. S12). These data suggest that tar-
geting mutant KRAS with CRISPR-Cas9 can control tumor growth
in vivo.
When similar experiments were conducted using HT29 cells,
which carry only wild-type KRAS, tumor growth and final tumor
sizes were not altered by doxycycline-induced induction of guide
RNA expression (Fig. 4C,D,F,H), indicating that expression of
Cas9 andmutant KRAS-targeting guide RNA does not affect the tu-
morigenesis, proliferation, or survival of cells that do not contain
mutant KRAS. Taken together, these data indicate that tumor con-
trol by CRISPR-Cas9 targeting mutant KRAS is restricted to tumors
with the relevant KRAS mutations, which is in line with in vitro
data shown above.
Intra-tumoral delivery of Cas9 and sgRNA targeting mutant KRAS
suppresses tumor growth in vivo
We finally evaluated whether such Cas9 and sgRNA delivery
can control human cancer growth in athymic mice. SW403
Figure 4. Targeting mutant KRAS with CRISPR-Cas9 blocks tumor growth in vivo. Cancer cells were
transduced with a lentiviral vector expressing the 35T9P17 sgRNA in a doxycycline-inducible manner
and a lentiviral vector that constitutively expresses Cas9. Transduced cells were subcutaneously injected
into immunodeficient mice to allow tumor formation over 14 d, after which the mice were treated with
doxycycline to induce expression of 35T9P17. Tumor growth was monitored for 12 d. (Hetero.)
Heterozygous, (Homo.) homozygous. (A,C ) Tumor growth curves. Red and blue lines represent doxycy-
cline-treated and untreated (control) groups, respectively. (B,D) Representative photographs of the mice
after 12 d of doxycycline treatment (26 d after tumor cell injection). (E–H) Representative photographs
(E,F ) and weights (G,H) of tumors removed from euthanized mice after 12 d of doxycycline treatment.
Error bars represent SEM. (∗) P < 0.05, (∗∗) P < 0.01, (∗∗∗) P < 0.001.
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cancer cells that contained the KRAS c.35G>T mutation were sub-
cutaneously injected into athymic mice, after which tumors
were allowed to form over 14 d. To deliver Cas9 and sgRNA
into the cancer cells, we first used lentiviral vectors. Intra-tumoral
injection of lentivirus expressing Cas9 and 35T9P17 sgRNA in-
hibited the tumor growth, which was in contrast to the robust tu-
mor growth in the control group injected with lentivirus
expressing only Cas9 (Fig. 5A–C; Supplemental Fig. S13A).
Immunohistochemical staining using an antibody against puro-
mycin acetyltransferase (PuroR), a protein that is expressed by
the lentiviral vector for 35T9P17 sgRNA and Cas9 expression
(Supplemental Fig. S4), showed that an average of 66% of tumor
cells were positive for PuroR, indicating that Cas9 and 35T9P17
sgRNA were delivered to the majority, but not all, of the tumor
cells (Supplemental Fig. S14A–E). The average indel frequency
at the target site at 6 d after the first lentiviral injection was
27.3% in tumor cells (Supplemental Fig. S14F). Considering
that SW403 cells also contain a wild-type KRAS allele that is bare-
ly targeted by the 35T9P17 sgRNA, ∼55% (=27.3% × 2) of tumor
cells would be expected to contain indels at the target sites. We
also used adeno-associated viral (AAV) vectors to deliver Cas9
and sgRNA into tumor cells, which likewise resulted in significant
control of tumor growth, albeit to a lesser extent than caused by
lentiviral delivery (Supplemental Fig. S15). Lentiviral delivery of
Cas9 and sgRNA into tumors generated using cancer cells with-
out mutant KRAS did not affect tumor growth, which was compa-
rable to the growth of those injected with lentivirus expressing
only Cas9 (Fig. 5D–F; Supplemental Fig. S13B), corroborating
the specificity of 35T9P17 sgRNA for cancer cells containing
the c.35G>T mutation.
Possibility of secondary oncogenic mutations in cells treated
with Cas9 and sgRNA
Given that targeting KRAS using Cas9 and sgRNA can induce var-
ious secondarymutations at or near the target sites, we cannot rule
out the possibility that some of these secondary mutations might
be oncogenic. To assess this point, we evaluated the genomic DNA
of human cells treated with Cas9 and sgRNA using deep sequenc-
ing. Reported KRAS oncogenic mutations include G12D, G12V,
G12C, G13D, G12R, G12A, and G12S (Cox and Der 2010). We
found that these secondary oncogenic mutations were barely ob-
served in either KRAS-mutant cancer cells (SW403) or cells con-
taining wild-type KRAS (HT29) either in vitro or in vivo after
lentiviral delivery of Cas9 and 35T9P17 sgRNA: The frequencies
ofmutations were similar to those ofmutations in cells transduced
with lentivirus that expressed only Cas9 (negative control)
(Supplemental Fig. S16A–C). We also observed that frequencies
of uncharacterized secondary nonsynonymous point mutations
that are not included in the reported oncogenic mutation list
described above were similar to those of negative controls, cells
transduced with the lentiviral vector expressing only Cas9
(Supplemental Fig. S16D–F). These results suggest that secondary
oncogenic point mutations are barely generated by Cas9 and
sgRNA-directed targeting of KRAS. However, we cannot rule out
the possibilities that targeting by Cas9 and sgRNA could induce
Figure 5. Intra-tumoral delivery of Cas9 and sgRNA targeting mutant KRAS suppresses tumor growth in vivo in immunodeficient mice. Cancer cells con-
taining mutant KRAS (A–C) or wild-type KRAS (D–F ) were subcutaneously injected into immunodeficient mice, after which tumors were allowed to form
over 14 d. Lentivirus expressing both Cas9 and sgRNA (35T9P17) (Lenti_Cas9-sgRNA) or control lentivirus expressing only Cas9 (Lenti_Cas9) were injected
into the tumors three times every 3 d. (A,D) Tumor growth curves. Black arrowheads indicate the times when the lentivirus was injected. The number of
tested tumors (n) = 6. (B,C,E,F ) Representative photographs (B,E) and weights (C,F ) of tumors removed from euthanized mice 15 d (B,C) or 12 d (E,F) after
the first lentiviral injection. Error bars represent SEM. (∗∗) P < 0.01, (∗∗∗) P < 0.001; (ns) not significant.
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secondary oncogenic point mutations at a frequency below the
detection limit (negative control) and that some in-frame indels
could potentially be oncogenic. Given that these secondary point
mutations and indels would be resistant to targeting by the sgRNA
that was initially used, we should consider the possibility that
clones resistant to targeting by Cas9 and the initially used sgRNA
could be generated when we use Cas9 and sgRNA for tumor
mass reduction.
Discussion
Programmable nucleases enable the targeting of specific genomic
sequences, and we now show that cells containing specific can-
cer-causing sequences can be selectively controlled both in vitro
and in vivo using CRISPR-Cas. In addition to mutant KRAS, other
genes bearing cancer-associated mutations can be disrupted using
CRISPR-Cas (Chen et al. 2017; Gebler et al. 2017; Koo et al.
2017); among these three studies, only two showed in vivo target-
ingof cancer-associatedmutations,which includedmutant epider-
mal growth factor receptor (EGFR) (Koo et al. 2017) and genomic
rearrangements (TMEM135–CCDC67 and MAN2A1–FER fusions)
(Chen et al. 2017), that led to control of tumor growth inmousexe-
nograft models. Compared to these two studies, our study is un-
precedented in that we target KRAS, the most frequently mutated
oncogene that cannot be targeted using any other clinically avail-
able anti-cancer agents such as small molecules or antibodies; mu-
tant EGFRcanbe targetedusing clinically available antibodies such
as gefitinib and erlotinib, and TMEM135–CCDC67 andMAN2A1–
FER fusions are much less frequent than KRAS mutations.
Furthermore, the two studies required a combinationof twoadeno-
viral vectors that deliver different cargos (Chen et al. 2017; Koo
et al. 2017), whereas our study used only one lentiviral vector, sim-
plifying the delivery component and expanding the list of possible
delivery methods. In addition, our approach does not require any
additional components such as ganciclovir (Chen et al. 2017) to
control tumor growth in vivo. This control of mammalian cells
containing specific sequences has parallels with sequence-specific
control exhibited in microbials (Bikard et al. 2014; Citorik et al.
2014). Sequence-specific antimicrobial activity can distinguish a
single-base change between two bacterial strains (Citorik et al.
2014), which is in line with our study showing that the selected
guide RNAs can distinguish between mutant and wild-type KRAS,
which differ by one base, in human cells. Our approach differenti-
ates cancer cells fromnormal cells based on the presence of the on-
cogenicmutations themselves, targeting“the root”of cancer rather
than subsequent changes that originate from the root.
So far, viral and nonviral approaches have been used to
deliver transgenes into cancer cells (Yin et al. 2014; Naldini
2015). Due to possible adverse effects of delivery into normal cells,
scientists have made substantial efforts to deliver transgenes
specifically into cancer cells, which often restricts the choice of ef-
fective delivery methods. Our approach is compatible with nonse-
lective methods that can deliver transgenes into both normal and
cancer cells because cells that lack target sequences should not ex-
perience significant adverse effects in the presence of Cas9 and
guide RNA, as we have shown in this study. However, we also can-
not rule out the possibility that Cas9 and sgRNA delivered to nor-
mal cells could elicit gain-of-function mutations in the KRAS gene
at an extremely low frequency that is below the detection limit of
the current study.
Furthermore, transient delivery of Cas9 and guide RNA is suf-
ficient for permanent target gene disruption, which is in contrast
with small interfering RNAs, which need continuous delivery for
target RNA inhibition (Zorde Khvalevsky et al. 2013). In summary,
our approach is compatible with a wide variety of delivery meth-
ods, including those that are transient or nonselective.
Our study provides a proof-of-concept that CRISPR-Cas9 can
be harnessed to target driver mutations in cancer without signifi-
cant alterations of normal genes to inhibit cancer growth both
in vitro and in vivo. Because the general mechanism of selective
target sequence recognition and subsequent gene disruption that
we utilized here is shared by other programmable nucleases such
as zinc finger nucleases, transcription activator-like effector nucle-
ases, and other types of CRISPR-Cas such as Cpf1 (Zetsche et al.
2015), tumor control may also be achieved using these other sys-
tems. Given that this tumor-controlling mechanism of CRISPR-
Cas differs from those of previously reported cancer therapies, in-
cluding conventional chemotherapy, radiotherapy, specific inhib-
itor or antibody therapy, and immunotherapy, combining
CRISPR-Cas with these other therapies could lead to additive or
synergistic effects. However, we also should note that the editing
efficiency of CRISPR on the oncogene is not 100% and that the
delivery efficiency of Cas9 and sgRNA to cancer cells is also not
100%, both of which would prevent this strategy from causing
complete tumor remission. Furthermore, we cannot rule out the
possibilities that Cas9-induced mutagenesis at the wild-type allele
could result in, albeit at extremely low efficiency, the generation of
oncogenic alleles and that the mutagenesis at the oncogenic mu-
tant allele could lead to the generation of other oncogenic mutant
alleles, which are resistant to targeting by the initially designed
sgRNA. Taken together, these issues indicate that CRISPR-Cas
would not be able to induce tumor remission in human patients
as a monotherapy, although it could be considered for reducing
the tumor volume before subsequent therapies such as surgery.
Furthermore, our successful application of CRISPR-Cas for target-
ing cancer driver mutations in vitro and in vivo can be utilized
for investigating the functional and regulatory pathways of onco-
genic drivers.
Methods
Cell lines and culture conditions
HEK293T cells (ATCC, CRL-11268) were purchased from the
American Type Culture Collection (ATCC). HT29, SW403,
SW480, SW620, LS513, and LoVo cells were obtained from the
Korean Cell Line Bank (KCLB). Details on the cell culture media
are in the Supplemental Methods.
Plasmids encoding Cas9 and sgRNA
A plasmid encoding Cas9, CMVpromoter-Cas9-2A-mRFP-2A-Puro
(hereafter, Cas9-Puro), was purchased from ToolGen. Cas9-Puro
was prepared by inserting 2A-mRFP-2A-Puro into pSpCas9(BB)-
2A-Puro V2.0 (Addgene, #62988). For sgRNA expression, the
hU6-sgRNA plasmid (ToolGen) was used. Oligonucleotides con-
taining each target sequence were synthesized (Bioneer) and
then annealed in vitro in a thermocycler. Annealed oligonucleo-
tides were ligated into the hU6-sgRNA plasmid digested with BsaI.
Reporter assay
Reporters containing target sequences of interest were prepared
as previously described (Ramakrishna et al. 2014). Briefly, oligo-
nucleotides containing target sequences (Fig. 1; Supplemental
Fig. S3) were synthesized (Bioneer) and annealed in vitro in a
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thermocycler. The annealed oligonucleotides were ligated into the
pRGS vector (Ramakrishna et al. 2014) predigested with EcoR1
and BamH1. HEK293T cells were transfected with mixtures of
the Cas9-puro, U6-sgRNA, and reporter plasmids at a weight ratio
of 1:1:1 using Neon electroporation (Invitrogen). Three days after
transfection, adherent cells were trypsinized and resuspended
in Ca2+- and Mg2+-free PBS (Gibco-BRL) supplemented with 2%
FBS. Single-cell suspensions were analyzed with FACSAria II (BD
Biosciences). We then calculated the percentage of mRFP+eGFP+
cells among the total population of mRFP+ cells, which represent-
ed the activity of the guide RNA on the target sequence.
Focus-forming assay
Cells double-transduced with lentivirus expressing Cas9 (Supple-
mental Fig. S4C) and lentivirus expressing sgRNA (Supplemental
Fig. S4A) as described above were seeded in six-well plates at a den-
sity of 1000 cells/well. After incubation for 10 d, the resulting col-
onies were rinsed with PBS, stained with 2% crystal violet,
photographed, and counted using ImageJ (Schneider et al. 2012).
Anchorage independence culture assay
The culture platform consisted of two soft agar (Dongin-Genomic)
layers (top, 0.4% agar; bottom, 0.6% agar) in DMEM supplement-
ed with 10% FBS in 60-mm dishes. Cells (105 per well) double-
transduced with lentivirus expressing Cas9 and lentivirus express-
ing sgRNA as described above were encapsulated in the top layer.
After 3 wk, colonies were stained with crystal violet for 16 h.
MTS cell proliferation assay
Cells double-transduced with lentivirus expressing Cas9 and lenti-
virus expressing sgRNAwere plated in 96-well culture plates at 1 ×
104 cells per well. MTS assays were performed 12, 24, 48, and 72 h
after cell plating. MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxy-
methoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium; CellTiter 96
Aqueous One Solution Cell Proliferation Assay, Promega) was add-
ed to each well at a proportion of 1/10, after which plates were in-
cubated for 4 h at 37°C. The medium was then removed and 180
µL DMSO was added to each well. The absorbance at 490 nm
was measured by a microplate reader (multiscan MK3; Thermo
Fisher Scientific). The mean cell proliferation was calculated
from the absorbance units.
Real-time cell analysis (RTCA)
Cells were double-transduced with lentivirus expressing sgRNA
and lentivirus expressing SpCas9, each at about 10–20 MOI.
Cells were added to the sensor wells of an E-plate 16 (Roche) at a
density of 5000 cells/well and incubated for 24 h before analysis.
Fifty microliters of DMEM was added to each well for the back-
ground measurement. The E-plate was incubated in the presence
of 5% CO2 at 37°C and monitored using the RTCA SP system
(Roche) for 48 h with time intervals of at least 15 min. Analysis
was performed using RTCA software version 1.2.1 (Roche).
Analysis of indel frequency
Genomic DNAwas isolated from cells after 72 h of lentiviral trans-
duction using a Wizard Genomic DNA Purification kit (Promega).
KRAS target sequences were PCR-amplified by Pfu DNA
Polymerase (SolGent) for indel frequency analysis. We used 13
µg of genomic DNA per sample as a template for the first PCR.
PCR products were purified with a MEGAquick-spin Total
Fragment DNA Purification kit (Intron). For the second PCR, 20
ng of purified PCR products from the first amplification were an-
nealed with both Illumina adaptor and barcode sequences. The re-
sulting productswere isolated, purified,mixed, and analyzed using
MiSeq or HiSeq (Illumina). Deep-sequencing data were sorted and
analyzed by previously described Python scripts (Kim et al. 2017a).
Data sorting was conducted based on 19-base barcode sequences.
Insertions or deletions located around the expected cleavage site
(i.e., an 8-bp region centered on the cleavage site) were considered
to be CRISPR-Cas9-induced mutations. Single-base substitutions
were exempted from the analysis. For secondary mutation analy-
sis, sequencing reads weremapped to the reference KRAS sequence
(NCBI) using the Burrows–Wheeler alignment algorithm (Li and
Durbin 2009). Mutations were then measured by an in-house
Python program (see Data access) and SAMtools (Li et al. 2009).
Intra-tumoral injection of lentivirus or AAV expressing Cas9
and sgRNA
Two million cancer cells were subcutaneously injected into the
flanks of 5-wk-old athymic male BALB/c nude mice (six mice per
group) and were allowed to form tumors over 2 wk. Each tumor
was directly injected with 1 × 108 TU lentivirus in 50 µL PBS or
with 1 × 1012 gc/ml AAV in 50 µL PBS with insulin syringes (BD
Biosciences, 31 gauge) three timeswith intervals of 3 d between in-
jections. Tumor size was evaluated every 3 d using a caliper. Mice
were sacrificed 5 wk after the tumor cell injection, and the tumors
were surgically isolated and weighed.
Immunohistochemistry
Micewere sacrificed by carbon dioxide asphyxiation. Tumors were
fixedwith 4% paraformaldehyde, embedded in paraffin, sectioned
at 5 µm, and stained with hematoxylin and eosin (H&E) for histo-
logical examination. Tumor sections were de-waxed, rehydrated,
and stained using standard immunohistochemistry protocols.
The following antibody was used: anti-puromycin acetyltransfer-
ase (PuroR) (1:500) (Kim et al. 2017b). The numbers of PuroR-pos-
itive and -negative tumor cells were quantified from >3 regions per
tumor. A total of at least 1000 tumor cells/tumor were counted.
Statistical analysis
All datawere expressed asmeans ± SEM, and statistical analysis was
conducted using IBM SPSS statistics (version 21). Student’s t-test
was used for the statistical analysis for continuous variables be-
tween two groups and ANOVA followed by multiple comparison
with Bonferroni’s method for variables among more than two
groups. A P value < 0.05 was considered statistically significant.
Data access
The deep sequencing data from this study have been submitted to
the NCBI Sequence Read Archive (SRA; http://www.ncbi.nlm.nih.
gov/sra/) under accession number SRP124382. A custom Python
code for mutation analysis is available at GitHub (https://github.
com/CRISPRJWCHOI/KRAS_CRISPR_CAS9) and as Supplemental
Code.
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